Recent Updates
Recently added Catalysts
BMEA Positive Sentiment

Biomea Fusion to Participate in Upcoming Investor Conferences

Key Takeaway: Biomea Fusion will participate in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and Citi's 2026 Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings to discuss their clinical-stage biopharmaceutical developments. The company focuses on therapies for diabetes and obesity.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences.
  • Management engagement in one-on-one meetings.
  • Focus on advancing therapies for diabetes and obesity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
12.1%
average across 11 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
icovamenib
Phase 2 · Type 2 Diabetes

Full Press Release Details

SAN CARLOS, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that members of its management team will participate in the following upcoming investor conferences:
• Jefferies Global Healthcare Conference in London: Biomea will participate in a fireside chat discussion on November 19, 2026, at 8:30 EST, 1:30 p.m. GMT in London, England. Management will also participate in one-on-one investor meetings during the conference.
• Citi's 2026 Global Healthcare Conference: Management will participate in one-on-one investor meetings on December 2, 2026, in Miami, Florida.
• Piper Sandler 38th Annual Healthcare Conference: Biomea will participate in a fireside chat discussion on December 3, 2026, at 1:30 p.m. ET in New York, New York. Management will also participate in one-on-one investor meetings during the conference.
Live audio webcasts of the Jefferies and Piper Sandler presentations will be available on the News & Events page of the Investors & Media section of Biomea's website. Webcast replays will be available following each presentation.
About Biomea Fusion Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.

Frequently Asked Questions

What conferences will Biomea Fusion attend?

Biomea Fusion will attend the Jefferies, Citi's, and Piper Sandler conferences.

When is the Jefferies Global Healthcare Conference?

The Jefferies conference is on November 19, 2026.

What is Biomea Fusion's focus area?

Biomea focuses on therapies for diabetes and obesity.

Will there be webcasts of the presentations?

Yes, live audio webcasts will be available on their website.

Last updated: Nov 12, 2026